Vaneltix Pharma, Inc.
June 18, 2025
Company Presentation
Other
153B
We are a private, clinical stage biotech in the therapeutic area of Women's Healthcare and Urology, bladder conditions which primarily affect women. We have 2 phase 2 assets, one with an ongoing funded development program through royalty financing, and a second is readying for phase 3 development and partnering process. We expect to have an asset launched in 2026 and are seeking investment to support our transformation into a phase 3 specialty pharma and potentially exit over the next 24 months.
Company HQ City:
New Brunswick,
Company HQ State:
NJ
Company HQ Country:
United States
Year Founded:
2018
Lead Product in Development:
Alenura
CEO
Dan Vickery
Development Phase of Lead Product
Phase II
Number of Unlicensed Products Looking for Licensing
5
When you expect your next catalyst update?
End of Phase 2 meeting for Alenura
What is your next catalyst (value inflection) update?
January 2026
Website
www.vaneltix.com
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}